Catabasis Pharma (CATB)
Catabasis Pharma
NASDAQ:CATB (9/8/2021, 8:06:56 PM)
After market: 8.63 +0.09 (+1.05%)8.54
-0.64 (-6.97%)
Company Profile
Catabasis Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 20 full-time employees. The company went IPO on 2015-06-25. Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The firm is focused on development and commercialization of therapeutics. The firm's lead product candidate is QLS-215. QLS-215 is a monoclonal antibody designed to inhibit plasma kallikrein for the treatment of hereditary angioedema, or HAE, a rare, debilitating and life-threatening disease. Plasma kallikrein is a critical component of HAE that causes pathologic vascular permeability, vasodilation and excessive tissue swelling. The firm is in the preclinical development for QLS-215 and to initiate a Phase I a clinical trial.
Company Info
Catabasis Pharma
100 High Street, 28th Floor
Boston MASSACHUSETTS 02110
P: 16173491971.0
CEO: Jill C. Milne
Employees: 20
Website: http://www.catabasis.com/
CATB News
3 years ago - Catabasis Pharmaceuticals, Inc.Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus
3 years ago - Catabasis Pharmaceuticals, Inc.Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
3 years ago - Catabasis Pharmaceuticals, Inc.Catabasis Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference
3 years ago - Catabasis Pharmaceuticals, Inc.Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference
3 years ago - StockNews.com2 Biotech Stocks Wall Street Predicts Will Rally By More Than 150%The Biotech industry has been instrumental in developing treatments for the coronavirus. The sector’s long-term potential remains solid due to the aging populating and the rising cost of healthcare. Wall Street analysts expect biotech stocks Sorrento Therapeutics (SRNE) and Catabasis Pharmaceuticals (CATB) to deliver exponential returns in the upcoming months.
CATB Twits
Here you can normally see the latest stock twits on CATB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
